All In MedTech

FDA Clearance Tracker · P140031-S130

SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valve Systems

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 17, 2021 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 17, 2021

Approved

Time to decision

73 days

Received Jul 6, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P140031-S130
Device name
SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valve Systems
Applicant location
Irvine, CA
Received
Jul 6, 2021
Decided
Sep 17, 2021
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P140031

Device type

Device class
Class III

Every decision under product code NPT

FDA's approval statement

As written in FDA's record.

Approval for modifications to the Instructions for Use to reflect the findings of the final Post-Approval Study (PAS) Report submitted for the SAPIEN 3 High or Greater Surgical Risk study

Source documents

Other decisions for Edwards Lifesciences, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.